
Global R&D Pipeline
My Favorite
Hot Targets:
5-HT2A receptor
Back
Total number of drugs
384
Phase II and later clinical stages
21.9%
Involving companies
391
Main therapeutic areas
Nervous System Diseases
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zotepine | Zotepine | Small molecule drug | Nervous System Diseases | Serotonin 2a (5-HT2a) receptor antagonists Dopamine D2 receptor antagonists | LTL Pharma Co., Ltd. | Astellas Pharma, Inc.Yungjin Pharm. Co., Ltd.LTL Pharma Co., Ltd.Sanofi | Approved | Japan Austria Czechia Germany South Korea Slovakia Taiwan Province | 1981-12-07 | Zotepine | detail > | ||||||||||
| Aripiprazole | Aripiprazole | Small molecule drug | Nervous System Diseases Congenital Disorders Other Diseases | Serotonin 1a (5-HT1a) receptor agonists Serotonin 2a (5-HT2a) receptor antagonists Dopamine D2 receptor agonists Dopamine D3 receptor agonists | Otsuka Holdings Co., Ltd. | Accord Healthcare SLOrimed Pharma, Inc.Otsuka Australia Pharmaceutical Pty Ltd.Otsuka Pharmaceutical Netherlands B.V.Sandoz GmbHZentiva ksOtsuka Pharmaceutical Co., Ltd.Xiamen LP Pharmaceutical Co., Ltd.Otsuka Holdings Co., Ltd.Korea Otsuka Pharmaceutical Co., Ltd.Lyndra Therapeutics, Inc.Odan Laboratories Ltd.Zhuhai Livzon Weiqiu Technology Co., Ltd.Chengdu Kanghong Pharmaceutical Group Co., Ltd. | Approved | Approved | United States China European Union Japan Canada Australia Iceland South Korea Liechtenstein Norway | 2002-11-15 | 2004-10-11 | United States | Aripiprazole | detail > | |||||||
| Perospirone Hydrochloride Hydrate | Perospirone Hydrochloride Hydrate | Small molecule drug | Nervous System Diseases | Serotonin 2a (5-HT2a) receptor antagonists Dopamine D2 receptor antagonists | Sumitomo Pharma Co., Ltd. | Livzon Group Livzon Pharmaceutical FactorySumitomo Pharma Co., Ltd. | Approved | Approved | China Japan | 2000-12-22 | 2008-04-22 | Perospirone Hydrochloride Hydrate | detail > | ||||||||
| Quetiapine Fumarate | Quetiapine Fumarate | Small molecule drug | Nervous System Diseases Other Diseases | Serotonin 2a (5-HT2a) receptor antagonists Dopamine D2 receptor antagonists | AstraZeneca Pharmaceuticals Co. Ltd. | AstraZeneca Pharmaceuticals Co. Ltd.Luye Pharma Group Ltd.Astellas Pharma, Inc.Acerta Pharma BVConsegna Pharma, Inc.CHEPLAPHARM Arzneimittel GmbHLTL Pharma Co., Ltd.Kyowa Pharmaceutical Industry Co., Ltd. | Approved | Approved | United States China Japan | 1997-09-26 | 2000-01-01 | China | Quetiapine Fumarate | detail > | |||||||
| Olanzapine | Olanzapine | Small molecule drug | Nervous System Diseases Other Diseases Congenital Disorders | Serotonin 2a (5-HT2a) receptor antagonists Serotonin 2c (5-HT2c) receptor antagonists 5-hydroxytryptamine receptors, ionotropic (HTR3) antagonists Dopamine D2 receptor antagonists | Eli Lilly & Co. | Glenmark Arzneimittel GmbHKrka dd Novo MestoViatris Ltd. (New Zealand)Teva Pharmaceuticals Europe BVCHEPLAPHARM Arzneimittel GmbHGlenmark Pharmaceuticals s.r.o.Eli Lilly & Co.Teva Branded Pharmaceutical Products R&D LLCPharmacor Pty Ltd.PARAPHARM DEVELOPMENT LIMITED | Approved | Approved | United States China European Union Japan United Kingdom Australia Iceland Liechtenstein Norway | 1996-09-27 | 1998-01-01 | China | Olanzapine | detail > | |||||||
| Risperidone | Risperidone | Small molecule drug | Nervous System Diseases Other Diseases | Serotonin 2a (5-HT2a) receptor antagonists Dopamine D2 receptor antagonists | Johnson & Johnson | Laboratorios Farmaceúticos Rovi SAShandong Luye Pharmaceutical Co., Ltd.Teva Canada Ltd.Consegna Pharma, Inc.Myung in Pharm Co., Ltd.Janssen Pharmaceuticals, Inc.Qilu Pharmaceutical Co., Ltd.HLS Therapeutics, Inc. | Approved | Approved | United States China European Union Japan Canada Iceland South Korea Liechtenstein Norway | 1993-12-29 | 2021-01-12 | Risperidone | detail > | ||||||||
| Sarpogrelate Hydrochloride | Sarpogrelate Hydrochloride | Small molecule drug | Cardiovascular Diseases | Serotonin 2a (5-HT2a) receptor antagonists | Tanabe Pharma Corp. | Tanabe Pharma Corp. | Phase 3 | Approved | China Japan | 1993-07-02 | Sarpogrelate Hydrochloride | detail > | |||||||||
| Clozapine | Clozapine | Small molecule drug | Nervous System Diseases Other Diseases | Serotonin 2a (5-HT2a) receptor antagonists Dopamine receptors antagonists Gamma-aminobutyric acid A receptor antagonists | HLS Therapeutics, Inc. | United Heritage Life Insurance Co.HLS Therapeutics, Inc.Douglas Pharmaceuticals America Ltd.AA Pharma, Inc.Novartis Pharma KKViatris Pty Ltd.Jiangsu Yixing Qianjin Pharmacy Factory | Approved | Approved | United States China Japan Canada Australia | 1985-01-01 | 1985-01-01 | Clozapine | detail > | ||||||||
| Bromperidol | Bromperidol | Small molecule drug | Nervous System Diseases | Serotonin 2a (5-HT2a) receptor antagonists Dopamine D2 receptor antagonists Dopamine D3 receptor antagonists | Approved | 1982-01-01 | Bromperidol | detail > | |||||||||||||
| Thioridazine | Thioridazine | Small molecule drug | Neoplasms Digestive System Disorders Immune System Diseases Hemic and Lymphatic Diseases | Serotonin 2a (5-HT2a) receptor antagonists Dopamine D1 receptor antagonists Dopamine D2 receptor antagonists Voltage-gated potassium channel subunit Kv11.1 blockers Alpha-1a adrenergic receptor antagonists Alpha-1b adrenergic receptor antagonists | Novartis Pharma AG | Beijing Sopuxingda Pharmaceutical Research Co., Ltd.Helmholtz Zentrum München | Phase 3 | Phase 3 | United States | 1978-10-18 | Thioridazine | detail > |
Total 384 data
1
2
3
4
5
6
...
38
39


